Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model

Nephrol Dial Transplant. 2008 Apr;23(4):1166-72. doi: 10.1093/ndt/gfm715. Epub 2007 Oct 28.

Abstract

Background: Chronic renal hypoxia is suspected to play a pathogenic role in the genesis of diabetic nephropathy (DN). Cobalt enhances the activity of the hypoxia-inducible factor (HIF), a key factor in the defence against hypoxia. Its long-term effect on DN is evaluated.

Methods: Cobalt chloride was given to hypertensive, type 2 diabetic rats with nephropathy (SHR/NDmcr-cp). Treatment was initiated at the age of 13 weeks and continued for 26 weeks.

Results: Cobalt did not correct hypertension and metabolic abnormalities (obesity, hyperglycaemia and hyperlipidaemia) but reduced proteinuria as well as histological kidney injury. Cobalt upregulated renal HIF-1alpha and HIF-2alpha expression and increased the expression of HIF-regulated genes, including erythropoietin, vascular endothelial growth factor and heme oxygenase-1. The renal expression of transforming growth factor (TGF)-beta and connective tissue growth factor (CTGF) was significantly reduced by cobalt. The renal expression of NADPH oxidase, a marker of oxidative stress, and the renal content of pentosidine, a marker of advanced glycation, were also significantly reduced by cobalt.

Conclusions: Cobalt achieved renal protection independently of metabolic status and blood pressure. Its effect was attributed to the upregulation of HIF and HIF-regulated genes and to a mitigated advanced glycation and oxidative stress.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimutagenic Agents / therapeutic use*
  • Arginine / analogs & derivatives
  • Arginine / metabolism
  • Basic Helix-Loop-Helix Transcription Factors / biosynthesis
  • Basic Helix-Loop-Helix Transcription Factors / genetics
  • Blood Pressure / physiology
  • Blotting, Western
  • Chromatography, High Pressure Liquid
  • Cobalt / therapeutic use*
  • Connective Tissue Growth Factor
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetic Nephropathies / etiology
  • Diabetic Nephropathies / metabolism
  • Diabetic Nephropathies / prevention & control*
  • Disease Progression
  • Gene Expression / drug effects
  • Glycation End Products, Advanced / metabolism
  • Hypertension / complications*
  • Hypertension / metabolism
  • Hypertension / physiopathology
  • Hypoxia / complications
  • Hypoxia / drug therapy*
  • Hypoxia / metabolism
  • Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis
  • Hypoxia-Inducible Factor 1, alpha Subunit / genetics
  • Immediate-Early Proteins / drug effects
  • Immediate-Early Proteins / metabolism
  • Insulin-Like Growth Factor Binding Proteins
  • Intercellular Signaling Peptides and Proteins / metabolism
  • Kidney / blood supply*
  • Kidney / metabolism
  • Lysine / analogs & derivatives
  • Lysine / metabolism
  • Male
  • NADPH Oxidases / biosynthesis
  • NADPH Oxidases / genetics
  • Obesity
  • Oxidative Stress / drug effects
  • Oxidative Stress / genetics
  • Polymerase Chain Reaction
  • RNA, Messenger / genetics
  • Rats
  • Rats, Inbred SHR
  • Transforming Growth Factor beta / biosynthesis
  • Transforming Growth Factor beta / genetics

Substances

  • Antimutagenic Agents
  • Basic Helix-Loop-Helix Transcription Factors
  • CCN2 protein, rat
  • Glycation End Products, Advanced
  • Hif1a protein, rat
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Immediate-Early Proteins
  • Insulin-Like Growth Factor Binding Proteins
  • Intercellular Signaling Peptides and Proteins
  • RNA, Messenger
  • Transforming Growth Factor beta
  • Connective Tissue Growth Factor
  • endothelial PAS domain-containing protein 1
  • Cobalt
  • Arginine
  • pentosidine
  • NADPH Oxidases
  • cobaltous chloride
  • Lysine